Here at diaTribe , we are constantly inspired by the huge number of organizations working to improve the lives of people with diabetes. On November 14, the IDF will host...

(S)he said what?!?

While Lantus (Sanofi’s insulin glargine) is the current standard for basal insulins, companies are still investing significant efforts to develop even better long-acting...

On June 16, FDA officials provided an update on its safety review of Takeda’s Actos (pioglitazone), announcing that going forward, prescribing information for Actos will...

The diaTribe team traveled to Amsterdam to attend the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD).

Kelly reflects on her recent visit to Washington…

In late August, the European Commission approved Boehringer Ingelheim/Eli Lilly’s DPP-4 inhibitor, Tradjenta, for type 2 diabetes. Tradjenta (also known as Trajenta in...

Recently, increasing evidence has suggested that weight-loss surgery (called “bariatric surgery”) can help improve type 2 diabetes management (or even cause its reversal...

(S)he said what?!?

On October 18, Reata and Abbott stopped their phase 3, 2,000-patient BEACON trial for the drug bardoxolone methyl, the most promising candidate in development for the...

Gary Scheiner shares how to make your blood glucose data work for you.

Earlier this month, the American Diabetes Association (ADA) and the co-chairs of the Senate Diabetes Caucus, Senator Susan Collins (R-ME) and Jeanne Shaheen (D-NH),...

In May, Johnson & Johnson submitted its SGLT-2 inhibitor canagliflozin for approval in the US. On average, the FDA takes about ten months to review applications for...

(S)he said what?!? Last updated September 13, 2012.

On November 14, the European Commission approved AstraZeneca and Bristol-Myers Squibb’s Forxiga (dapagliflozin) for type 2 diabetes throughout the European Union...

Visiting your healthcare team? Kerri Sparling highlights the right questions to ask.

Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.

As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...

(S)he said what?!?

The giant Consumer Electronics Show, held each January in Las Vegas, had a variety of devices relevant to diabetes and obesity this year. Media buzz surrounded the...